Dutch Unilever revenue rockets due to lockdown cooking

Photo: EPA

Pandemic lockdowns had awful influence on several major industries and companies, but the beverage and cosmetics conglomerate Unilever found its way to stay on the profit path on the back of strong demand from emerging markets and end-consumers, Reuters reported. Consumers, locked in their homes were more likely to cook often and use more of Unilever’s products which include food ingredients, soaps, cosmetics, etc. The company announced it would use some of its returns to facilitate a buyback programme worth nearly 3 billion euros of the firm’s stocks.

Unilever easily beat quarterly sales as underlying sales rose 5.7% in the three months to the end of March, topping analysts' average forecast of 3.9%, according to a company supplied consensus. "We have had a good start to the year. We are growing faster than our markets," finance chief Graeme Pitkethly told reporters.

The group it was confident of delivering full-year sales growth within its mid-term target range of 3-5%, with the first half around the top of the range. Some analysts had doubted whether it would hit that goal this year. Unilever also said it expected a slight increase in underlying operating margin this year. The sales in the group's food and refreshments business jumped 9.8% in the quarter, helped by strong demand for home consumption in North America and Europe. Emerging markets saw growth of 9.4%, led by double-digit increases in China and India following strict lockdowns the previous year.

Similar articles

  • Covid-19 vaccine makers slump on expected patent waiver

    Covid-19 vaccine makers slump on expected patent waiver

    The stocks of all companies involved in production of Covid-19 vaccines fell, as US and EU backed the call from the World Health Organisation to waive patent rights claims over the jabs production, Reuters reported. The share slumps came even as some analysts raised doubts about any near-term pressure on Covid-19 vaccine sales from discussions of waiving intellectual property rights, given the manufacturing complexity and scarcity of raw materials. Combined, Pfizer and Moderna have forecast a total of over $45 billion in sales this year for their Covid-19 vaccines.

  • Tesla misses key technology target

    Tesla misses key technology target

    The producer of electric cars Tesla admitted it would miss a target set by its majority owner Elon Musk - to develop full self-driving vehicles by the end of 2021, Reuters reported. The announcement seriously undermines Tesla ambitions to influence the global EV market. Documents released in media earlier this week showed that the company is falling behind announced deadlines while incidents with EVs continue to rise.

  • Bayer loses court fight over EU pesticides

    Bayer loses court fight over EU pesticides

    The German chemical conglomerate Bayer lost an appeal in EU court against a ban related to the usage of pesticides amid growing concerns linked to the extinction on bees, Reuters reported. The European Union's top court upheld the EU's partial ban on insecticides linked to harming bees, preventing their use on certain crops. Bayer appealed to overturn a lower EU court's 2018 decision to uphold the EU ban.